Spotlight on Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women with Disease Progression Following Antiestrogen Therapy

By Kate McKeage   Monique P. Curran   Greg L. Plosker  

American Journal of Cancer, Vol. 3, Iss. 4, 2004-01 ,pp. : 267-270

Adis International

Access to resources Recommend Favorite

Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer

By Esteva Francisco   Moulder Stacy   Gonzalez-Angulo Ana   Ensor Joe   Murray James   Green Marjorie   Koenig Kimberly   Lee Mong-Hong   Hortobagyi Gabriel   Yeung Sai-Ching  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 63-72

Springer Publishing Company

Access to resources Recommend Favorite

Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer

By Delpech Y.  

Breast Cancer Research and Treatment, Vol. 135, Iss. 2, 2012-09 ,pp. : 619-627

Springer Publishing Company

Access to resources Recommend Favorite

Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer

By Sørensen Kristina   Thomassen Mads   Tan Qihua   Bak Martin   Cold Søren   Burton Mark   Larsen Martin   Kruse Torben  

Breast Cancer Research and Treatment, Vol. 142, Iss. 3, 2013-12 ,pp. : 529-536

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic factors in patients with isolated recurrences of breast cancer (stage IV-NED)

By Juan O.   Lluch A.   Paz L.d.   Prósper F.   Azagra P.   Marugán I.   Martínez-agulló A.   Garcia-conde J.  

Breast Cancer Research and Treatment, Vol. 53, Iss. 2, 1999-01 ,pp. : 105-112

Springer Publishing Company

Access to resources Recommend Favorite